neurosense-tx.com (NRSN): Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization
The market trend for the EV/EBITDA multiple for NeuroSense Therapeutics (NRSN) stands at 0.00. The business relies on developing drugs for neuron degeneration, where high patent profitability ensures global reach with low costs. NeuroSense Therapeutics (NRSN) is implementing advanced RNA regulation methods to combat ALS, focusing its current strategy on preparing for the final stages of clinical trials and obtaining regulatory approvals.
NRSN (neurosense-tx.com): analytical breakdowns and indicator data
- stock price and consensus target price:
- stock exchange capitalization data:
- book value of equity indicators:
- debt and solvency information:
Total Debt to Capital NeuroSense Therapeutics|NRSN - Long-Term Liabilities to Capital|Short-Term Debt to Equity NeuroSense Therapeutics Ltd.|NRSN - Company Aggregate Debt|Debt to Book Capitalization Ratio NeuroSense Therapeutics|NRSN - Long-Term Debt Volume|Company Short-Term Debts NeuroSense Therapeutics|Quick Liquidity Indicator neurosense-tx.com
- business earnings and investment ratios data:
NRSN - Final Profit|Future Profit NeuroSense Therapeutics|NRSN - Market Price to Net Income Ratio|Forward P/E Multiple NeuroSense Therapeutics Ltd.|NRSN - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple NeuroSense Therapeutics|NRSN - Profit before interest, taxes and amortization|Earnings per share for the last twelve months NeuroSense Therapeutics|NRSN - Earnings per share for the trailing year|Quarterly EPS earnings growth neurosense-tx.com|NRSN - Earnings growth in current year|Net earnings per share growth forecast for next year NeuroSense Therapeutics
Fundamental company valuation:NRSN (NeuroSense Therapeutics, Ltd.)
This ratio compares the total value of assets and debt to operating income before depreciation and amortization, allowing for an assessment of the business's real value without the influence of the tax regime. For NeuroSense Therapeutics (NRSN), which operates in the underserved ALS therapy segment, this metric reflects an investment advance into future profits, making the company's EV/EBITDA multiple chart a key indicator of whether the asset is overvalued or undervalued.
Analysis of competing companies
Biogen Corp - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple Neurocrine Corp NBIX|RGC - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation AXSM (axsome.com)|ACADIA Pharmaceuticals Inc. (ACAD) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Xenon Pharmaceuticals Inc. (XENE)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Viking Pharma|Supernus Corp (SUPN) - Total Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple CPRX|DNLI - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Harmony Biosciences Holdings, Inc. HRMY|BHVN: Enterprise Value to Operating Income Before Depreciation|AMLX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Total Company Value to Operating Income Before Depreciation Ratio Trevi Corp TRVI|PRAX: EV/EBITDA Multiple|Company Value to EBITDA anavex.com (AVXL)|Enterprise Value to EBITDA Ratio CBLL|PRTA: Business Value to Operating Income Before Depreciation|Enterprise Value to EBITDA Ratio ALEC (Alector, Inc.)|Enterprise Value to Operating Income Before Depreciation Ratio ANNX|EV/EBITDA Multiple OMER (Omeros)|Business Value to Operating Income Before Depreciation NGNE|AC Immune SA - EV/EBITDA Multiple|Company Value to EBITDA Voyager Therapeutics Inc|Neumora Therapeutics Inc (NMRA) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Scilex Holding Company, Inc. - Business Value to Operating Income Before Depreciation|TVGN (Tevogen Bio Holdings) - EV/EBITDA Multiple|EV/EBITDA Multiple Alpha Cognition Corp|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Cognition Therapeutics, Inc. (CGTX)|IKT: Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple SAVA (Cassava)|Assertio Holdings (ASRT) - Company Value to EBITDA|COYA: Enterprise Value to EBITDA Ratio|VTGN - EV/EBITDA Multiple|OVID (ovidrx.com) - Enterprise Value to EBITDA Ratio|ABOS: Enterprise Value to Operating Income Before Depreciation Ratio|CRVO (CervoMed Inc) - EV/EBITDA Multiple|Alterity Therapeutics Ltd (ATHE) - Total Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple CLNN|Enterprise Value to EBITDA Ratio pepgen.com PEPG|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Jupiter Neurosciences JUNS|Total Company Value to Operating Income Before Depreciation Ratio Relmada Therapeutics Inc (RLMD)|ANVS - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|GRCE (Grace Therapeutics, Inc.) - Enterprise Value to Operating Income Before Depreciation|Firefly Neuroscience, Inc (AIFF) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Klotho Neurosciences - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Reviva Pharmaceuticals Holdings, Inc.|MetaVia, Inc. (MTVA) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization NeurAxis, Inc (NRXS)|heliusmedical.com - Enterprise Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Passage Bio PASG|NEUP: Enterprise Value to Operating Income Before Depreciation|Minerva Neurosciences, Inc. - EV/EBITDA Multiple|Company Value to EBITDA Athira Pharma Inc|ADXN (Addex Therapeutics, Ltd.) - Enterprise Value to EBITDA Ratio|Alzamend Neuro (ALZN) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Cyclerion Therapeutics Inc.|PTIX: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Pasithea Therapeutics (KTTA)|CRGT - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Avenue Therapeutics, Inc ATXI|BCLI: Enterprise Value to Operating Income Before Depreciation|Cara Therapeutics, Inc. - EV/EBITDA Multiple|Company Value to EBITDA chromocell.com|ELYM (eliemtx.com) - Enterprise Value to EBITDA Ratio|Intra-Cellular Therapies, Inc. (ITCI) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Longboard Pharma|MRNS: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization NKGen Biotech, Inc. (NKGN)|NRBO - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Sage Therapeutics SAGE|Total Company Value to Operating Income Before Depreciation Ratio Synaptogenix Inc. (SNPX)|Trevena, Inc - EV/EBITDA Multiple|Company Value to EBITDA Vigil Neuroscience|Anew Medical, Inc. (WENA) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation CERE
